IL-22: A Potent Therapeutic Protein with Multiple Functions (G50616)

Target Name: IL22

NCBI ID: G50616

IL22

IL-22: A Potent Therapeutic Protein with Multiple Functions

The IL-22 protein is a cytokine that plays a crucial role in the regulation of immune responses and cell growth. It is a member of the Interleukin-2 family of cytokines, which include IL-1, IL-2, IL-3, and IL-4. IL-22 is produced by T-cells and NK cells in response to an infection or injury and has been shown to have potent immune-modulating effects.

One of the key functions of IL-22 is its ability to stimulate the production of CD4+ T cells. CD4+ T cells are a crucial part of the immune system and are responsible for cell-mediated immunity. They are important for fighting off infections and for Maintaining the overall health of the body. IL-22 has been shown to be a potent stimulator of CD4+ T cell production in both humans and animals.

Another important function of IL-22 is its ability to stimulate the production of natural killer cells (NK cells). NK cells are a type of immune cell that play a key role in fighting off infections and cancer. IL-22 has been shown to be a potent stimulator of NK cell production in both humans and animals.

IL-22 has also been shown to have pro-inflammatory effects. When the body is under attack, IL-22 is produced in response to the infection or injury and helps to stimulate the production of other pro-inflammatory cytokines. This increase in pro -inflammatory cytokines can lead to tissue damage and inflammation. However, IL-22 has also been shown to have anti-inflammatory effects. It can inhibit the production of pro-inflammatory cytokines and reduce tissue inflammation.

IL-22 has been shown to have a variety of potential therapeutic applications. For example, it has been shown to be an effective treatment for a variety of skin cancers, including basal cell carcinoma, squamous cell carcinoma and melanoma. IL-22 has also been shown to be an effective treatment for a variety of autoimmune diseases, including rheumatoid arthritis, autoimmune gastritis and psoriasis.

IL-22 has also been shown to have potential applications in regenerative medicine. For example, IL-22 has been shown to be an effective stimulator of peripheral blood stem cell (PBSC) proliferation and differentiation into functional immune cells, such as T-cells and natural killer cells. This may have potential applications in the development of immune-based therapies for a variety of diseases.

In addition to its potential therapeutic applications, IL-22 is also a drug target. Several studies have shown that IL-22 can be targeted by small molecules and antibodies and that it plays a role in a variety of cellular processes. For example, one study shows that IL-22 can be inhibited by the small molecule drug, PD-L1, which is currently being developed as a cancer therapeutic.

Overall, IL-22 is a protein that has a variety of potential therapeutic applications. Its ability to stimulate CD4+ T cell and NK cell production, as well as its anti-inflammatory and immunomodulatory effects, make it an attractive target for further research and development . Additionally, its potential as a drug target makes it a promising area for future therapeutic development.

Protein Name: Interleukin 22

Functions: Cytokine that plays a critical role in modulating tissue responses during inflammation (PubMed:17204547). Plays an essential role in the regeneration of epithelial cells to maintain barrier function after injury and for the prevention of further tissue damage (PubMed:17204547). Unlike most of the cytokines, has no effect on immune cells. Signals through a heterodimeric receptor composed of two subunits, the specific receptor IL22RA1 which is present on non-immune cells in many organs and the shared subunit IL10RB (PubMed:10875937, PubMed:18599299). Ligation of IL22RA1 with IL22 induces activation of the tyrosine kinases JAK1 and TYK2, which in turn activates STAT3. In turn, promotes cell survival and proliferation through STAT3, ERK1/2 and PI3K/AKT pathways (PubMed:25793261, PubMed:31311100)

The "IL22 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IL22 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets